Background: It is unclear how inequalities in survival among children with acute lymphoblastic
Introduction
Acute Lymphoblastic Leukemia (ALL) is the most common childhood cancer in the United States (1) , and one of the most curable cancers. Treatment advances, such as the introduction of combination chemotherapy and effective treatment for subclinical central nervous system (CNS) leukemia in the 1960s, and the development of risk-based therapy placed on well-designed clinical trials in the 1980s (2) , have contributed to dramatic improvements in survival among children with ALL. The overall 5-year survival probability improved from less than 10% in early 1960s (1) to over 80% in late 1990s (3) .
Despite milestones in survival improvements, previous studies identified continuing inequalities in childhood ALL survival, with adverse prognosis reported in Blacks, Hispanics, American Indian/Alaska Natives (AIANs), children aged <1 and 10-19 years at diagnosis, and boys (4-7).
In the 1990's and 2000's, ALL survival further improved following several medical advances: better precision in treatment with applications of molecular biological tools (2); a uniform system of risk classification (8) ; and the merging in 2000 of the Children's Cancer Study Group and the Pediatric Oncology Group (POG) into the Children's Oncology Group (COG), providing advanced care for over 90% of US childhood cancer patients (9) and two thirds of childhood ALL patients (10) . Consequently, in 2000-04, children diagnosed with ALL at 0-14 years in the US are reported to have an overall 5-year survival probability of 87.5% as compared to 80.2% in 1990-94 (11) .
With continued treatment and survival improvement, several studies have reported decreased inequality in survival among Blacks and Whites. For patients enrolled in COG trials, the hazard ratio of all-cause mortality in Blacks relative to Whites aged 0-21 years was reported to drop from 1.73 in 1990-94 to 1.37 in 2000-05 (10) .A population-based study also reported narrowed gap in survival between Blacks and Whites: 5-year survival rates for Blacks and Whites, respectively, increased from 56.6% and 76.3% in [1981] [1982] [1983] [1984] [1985] [1986] [1987] [1988] [1989] [1990] to 86.1% and 88.9% in 2001-10 (12) . However, research is limited regarding how the inequalities in survival among children of other race/ethnicity groups (Hispanics, Asian/Pacific Islanders (APIs), and AIANs) as compared to Whites have changed over time, and whether racial/ethnic inequalities in survival vary by age at diagnosis and sex.
The current study sought to determine how inequalities in survival after childhood ALL by race/ethnicity have changed over the period 1975-2010 and describe the inequality in survival among US children with ALL by race/ethnicity, age at diagnosis and sex in the period 2000-10.
Materials and Methods

Study population
Data were obtained from the original nine population-based cancer registries in the National Cancer registries were included. ALL cases were ascertained according to the International Classification of Diseases for Oncology, Third Edition (14) . Six cases identified through autopsy/death certificate, and 47 cases with missing race/ethnicity information were also excluded.
Race and Hispanic ethnicity data in SEER registries are generally derived from information abstracted from patients' medical records and is mainly based on self-or caregiver-report, but may be based on medical staff observation (15) . Hispanic identification was additionally enhanced using the North American Association for Central Cancer Registries Hispanic-Latino identification algorithm (16) , which is based on surnames and birthplace. Mutually-exclusive racial/ethnic categories were defined as:
Hispanics, non-Hispanic-Whites (NH-Whites), non-Hispanic-Blacks (NH-Blacks), APIs, and AIANs.
Four diagnosis periods (1975-83, 1984-91, 1992-99 and 2000-10) were selected to capture relevant secular trends in treatment improvements and to allow sufficient follow-up for reliable estimates. Age at diagnosis was categorized as <1, 1-9 and 10-19 years, based on NCI's risk classification for ALL (8) .
Follow-up for vital status is conducted by the SEER cancer registries using linkages to national and state vital statistics records. Follow-up in this study was through the end of 2011, with a median follow-up of 8.9 years. Death due to ALL (ALL mortality) was the primary outcome of interest, which was ascertained based on the SEER cause-specific death classification (17) . Cases who were alive during the follow-up were censored at the last active follow-up. Those who died of causes not attributable to ALL had their atrisk status terminated on the date of death. Death due to all causes was analyzed as the secondary outcome (Supplementary Table 1 and 2) .
Statistical analyses
Characteristics of cases were tabulated and compared among the five race/ethnicity groups, using chisquare tests. Cumulative ALL mortalities among cases and their 95% confidence intervals (CIs) were estimated using the cumulative incidence function (18) . Multivariable Cox regression was applied to estimate ALL mortality hazard ratios (HRs) and their 95% CIs associated with race/ethnicity, sex, and age at diagnosis, adjusting for each other, stratified by diagnosis period. The age-specific HRs adjusting for sex, and sex-specific HRs adjusting for age, associated with race/ethnicity, stratified by diagnosis period were also analysed using multivariable Cox regression. Tests of a linear trend in the change of inequalities with respect to a variable (e.g., race/ethnicity) over time were performed by treating the fourcategory diagnosis period variable as continous in the interaction term of the diagnosis period and the variable in the Cox regression models. Proportional hazard assumptions were checked using scaled Schoenfeld residuals (19) by 'estat phtest' command in Stata and confirmed. Kaplan-Meier methods were used to estimate the overall survival. Two-sided P-values (P) were reported and those less than 0.05 were considered as statistically significant. Stata, version 12.0 was used for all analyses, except for the cumulative incidence calculation which was done in SAS, version 9.4. Cumulative incidence curves were plotted using R, version 2.13.1.
Results
A total of 7365 children were included and their characteristics by race/ethnicity are shown in Table 1 . Table 2 shows the 5-year cumulative ALL mortalities by race/ethnicity, age at diagnosis, and sex within each diagnosis period. Figure 1 compares cumulative ALL mortality curves across race/ethnicity groups in each diagnosis period, which illustrates the change in inequalities of ALL mortality among different race/ethnicity groups over the four diagnosis periods. Table 1 ). The overall 5-year survival probability increased from 61% in 1975-83 to 88% in 2000-10 among all children with ALL.
Girls had better survival than boys historically. The 5-year cumulative mortality decreased from 30% (95% CI, 26%-33%) in 1975-83 to 9% (95% CI, 7%-11%) in 2000-10 in girls, and from 39% (95 CI, 35%-42%) to 11% (95 CI, 10%-13%) in boys. Children diagnosed with ALL at 1-9 years old had better survival than <1 and 10-19 years old, such inequality persisted in magnitude in 2000-10, with a 5 year cumulative ALL mortality of 5% (95% CI, 4%-7%), 20% (95% CI, 17%-23%) and 31% (95% CI, 21%-41%) in children aged 1-9, 10-19 and <1 year, respectively. Table 3 shows the adjusted ALL mortality HRs for race/ethnicity, sex, and age at diagnosis by diagnosis period. Compared to NH-Whites, after adjusting for age at diagnosis and sex: the HR in NH-Blacks Table 2 ).
Age-specific and sex-specific HRs for race/ethnicity by diagnosis period are shown in Table 4 .
Similar racial/ethnic inequalities trends were observed in each age at diagnosis group, and among boys and girls. However, racial/ethnic inequalities varied by age at diagnosis and by sex. The racial/ethnic inequalities were the largest among age 1-9 years except for AIANs. 
Discussion
Treatment advance in curing most children with ALL has been considered as one of the greatest successes in the history of cancer research. Yet, not all subgroups benefit equally. This study documents the inequality trends over time by race/ethnicity, age at diagnosis and sex, based on ALL cases from SEER 9 registries over 3.5 decades. Cumulative ALL mortality, overall survival probability, and adjusted ALL Overall, we found that as compared to NH-Whites, the relative inequalities in ALL mortality decreased in NH-Blacks, but increased over time in other minority groups (Hispanics, APIs, and AIANs), significantly among Hispanics. In 2000-10, NH-Blacks diagnosed at 1-9 years old, Hispanics diagnosed at 1-9 and 10-19 years old, APIs diagnosed at 1-9 years old and AIANs diagnosed at 10-19 years old had about twice the hazard rates of ALL mortality than their NH-White counterparts diagnosed at the same age group.
Moreover, larger inequalities were observed among Hispanic girls than boys, and inequality was observed only among API boys but not girls, as compared to their NH-White counterparts.
Survival inequality between NH-Blacks and NH-Whites was the highest between 1984 and 1991 and then declined afterwards. These differences for 1984-1991are illustrated in Figure 1 and are the result of substantial improvement in survival among NH-Whites but limited improvement in NH-Blacks from the preceding period. These observations may suggest that advances in therapy were more easily accessed by the NH-White children as compared with their NH-Black counterparts. The decreasing inequality observed between NH-Whites and NH-Blacks is consistent with previous findings (10, 12) . In 2000-10, NH-Blacks had 3% higher in absolute values of 5-year cumulative ALL mortality and an adjusted ALL mortality HR of 1.21 which did not differ statistically from NH-Whites. Previously, Hunger et al.
reported narrowed inequality between White and Black patients enrolled in COG trials, and they reported all-cause mortality as opposed to ALL-specific mortality (10) . Our population-based study allows us to better generalize our results to the US population, especially considering that access to care and enrollment in clinical trials is usually an important driver of mortality differences. Another recent study with ALL at 0-14 years (12). However, this study included ALL cases in SEER 18 registries so the secular trends might be impacted by the appreciable changes in the SEER population, starting with the 9 registries in 1975, which we studied in this report for consistency over time, to 18 registries in 2000.
Blacks are known to have a higher incidence of the T-cell subtype of ALL as compared to Whites, which in general has a worse prognosis (7, 10) ; however, ALL immunophenotype information is limited in SEER data. The "grade" variable in SEER data shows immunophenotype information for leukemia.
However, the use of this variable is cautioned, especially for cases diagnosed in 1973-2000 due to the change of reporting requirements and medical terminology over time. Moreover, for cases included in the current study, the immunophenotype information is missing for more than half of the cases. Treatment improvement, e.g., the application of more intensive treatment protocols, and the approval of Nelarabine There was a statistically significantly widening trend in the relative inequalities in ALL mortality hazards between Hispanics and NH-Whites. This shows that, as a group, the relative improvement following ALL treatment advances has been slower in Hispanics than in NH-Whites. An important factor in interpreting this result is the change in the US Hispanic population in the study regions over the study time period. 
2000-10, primarily due to immigration. In some, but not all, of the 9 SEER registries, we found statistically significant or marginally significant increasing trends in inequalities among Hispanics as compared to NH-Whites (Supplementary Table 3 APIs had similar survival as NH-Whites historically, as consistent with previous studies (5). However, albeit non-significant, relative inequalities between APIs and NH-Whites grew over time, especially among cases diagnosed at age 1-9 years. Moreover, the current study found APIs aged 1-9 years had over two-fold ALL mortality hazard (95% CI, 1.10-3.69), and API boys had an HR of 1.61 (95% CI, 1.00- cases limited analyses of distinct API ethnic groups. We found that a large inequality between AIANs and NH-Whites persisted over time. Results on AIANs should be interpreted with caution, as there were only 111 AIAN cases in the current study. However, this study is to our knowledge the largest and the first study that documents the trend of inequalities between AIANs and NH-Whites in ALL survival over time.
Sex differences in ALL survival are partially explained by sex differences in the distributions of ALL immunophenotype and DNA index (6). Higher mortality among boys than girls persisted over the time period (HRs around 1.3) . However, treatment advance has decreased absolute inequality in the cumulative ALL mortality between boys and girls. (25, 26) . Children diagnosed at 10-19 years old are less likely to enroll in pediatric trials than children diagnosed at 1-9 years old (10) . These may be, at least partly, associated with the fewer improvements have been made for treating infants and adolescents with ALL.
Even though children diagnosed with ALL at age 1-9 years old have the best prognosis and experience the most treatment advances and survival improvement compared to children diagnosed at other age groups, the racial/ethnic inequalities between NH-Whites and other minority groups (NH-Blacks, Hispanics, and APIs) have been observed to be the largest among them. Although our population-based analyses do not include data that allow us to examine specific underlying causes of these differences in survival by race/ethnicity, possible explanations include both biological and sociocultural causes. Pollock et al. found African-Americans enrolled in POG clinical trials presented with worse disease presentations (e.g., higher white blood cell (WBC) counts, and common ALL antigen) than Whites which were associated with subsequent treatment failures (7) . Genomic rearrangement of cytokine receptor-like factor 2 was found to be more common among Hispanics and is associated with poor outcome in pediatric B-progenitor ALL (27) . A component of genomic variation that co-segregated with Native American ancestry was associated with risk of ALL relapse (28) . However, adjusting for some biological differences, inequalities between the racial/ethnic minorities and NH-Whites were still observed (7). Access and adherence to the treatment are also likely explanations for the inequalities. Lund Third, causes of death might have been misclassified in determining ALL mortality. The SEER causespecific death classification is defined based on cause of deaths in conjunction with the tumor sequence, site of the original cancer diagnosis; and comorbidities, aiming to capture deaths that are related to the specific cancer but are not coded as such (17) . To supplement this limitation, death due to all causes was analyzed as the secondary outcome, and similar results were found and presented in the supplementary materials. However, some other important endpoints, such as the event-free survival, cannot be estimated as treatment failure information (e.g. relapse or refractory disease) is not captured by SEER data.
Moreover, the lack of information regarding clinical presentation (e.g., WBC counts), tumor biology, and treatment of ALL cases in cancer registries limits the interpretation of the inequalities and their trends.
Lastly, the inequalities and their trends found on the SEER 9 registries may not be fully applicable to other SEER registries and to other geographic locations outside of the SEER program.
In conclusion, survival inequalities changed differently across subgroups of children with ALL.
Underlying causes of the differential trends need to be examined, such that targeted interventions can be developed to reduce growing or persistent inequalities among Hispanics and AIANs, as well as among APIs boys, APIs and NH-Blacks diagnosed at 1-9 years old. 
